Nature Communications (Jun 2021)
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
- Nitin Roper,
- Moises J. Velez,
- Alberto Chiappori,
- Yoo Sun Kim,
- Jun S. Wei,
- Sivasish Sindiri,
- Nobuyuki Takahashi,
- Deborah Mulford,
- Suresh Kumar,
- Kris Ylaya,
- Christopher Trindade,
- Irena Manukyan,
- Anna-Leigh Brown,
- Jane B. Trepel,
- Jung-Min Lee,
- Stephen Hewitt,
- Javed Khan,
- Anish Thomas
Affiliations
- Nitin Roper
- Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH
- Moises J. Velez
- Department of Pathology and Internal Medicine, University of Rochester
- Alberto Chiappori
- Moffitt Cancer Center
- Yoo Sun Kim
- Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH
- Jun S. Wei
- Genetics Branch, Center for Cancer Research, NCI, NIH
- Sivasish Sindiri
- Genetics Branch, Center for Cancer Research, NCI, NIH
- Nobuyuki Takahashi
- Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH
- Deborah Mulford
- Department of Pathology and Internal Medicine, University of Rochester
- Suresh Kumar
- Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH
- Kris Ylaya
- Laboratory of Pathology, Center for Cancer Research, NCI, NIH
- Christopher Trindade
- Laboratory of Pathology, Center for Cancer Research, NCI, NIH
- Irena Manukyan
- Laboratory of Pathology, Center for Cancer Research, NCI, NIH
- Anna-Leigh Brown
- National Center for Biotechnology Information, NIH, NLM
- Jane B. Trepel
- Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH
- Jung-Min Lee
- Women’s Malignancies Branch, Center for Cancer Research, NCI, NIH
- Stephen Hewitt
- Laboratory of Pathology, Center for Cancer Research, NCI, NIH
- Javed Khan
- Genetics Branch, Center for Cancer Research, NCI, NIH
- Anish Thomas
- Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH
- DOI
- https://doi.org/10.1038/s41467-021-24164-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Immune checkpoint blockade (ICB) benefits only a small subset of patients with small cell lung cancer (SCLC) and the mechanisms driving benefit are poorly understood. Here, the authors show that elevated Notch signaling predicts clinical benefit in ICB in relapsed SCLC.
